Company intelligence / Profile preview

Aurora Medicine

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Completed Phase I/II trials for AU-101 in Sarcoma (Osteosarcoma) showing safety, tumor killing efficacy, and survival benefits; completed AU-105 trial in Glioblastoma showing safety, ORR signals, and doubled historic survival; ongoing Phase I/II trials for AU-101 in Osteosarcoma and Glioblastoma; planned Phase IIB/III for AU-105 and Phase II for breast cancer[1][6].

Therapeutic areas: Oncology
Modalities: CAR-T cell therapy
Industry: Biotech

Drug pipeline

1 asset

Pedanios

Unknown

Beyond the preview

Go deeper on Aurora Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurora Medicine.

Explore the full profile